SCHEMBL2205463

SCHEMBL2205463

Cc1cc(Nc2nc(Sc3ccc(F)cc3F)nc3ccccc23)[nH]n1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AURKA O14965 14/20 0.52
GSK3B P49841 13/20 0.52
AURKB Q96GD4 9/20 0.52
SRC P12931 6/20 0.48
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
AURKC Q9UQB9 1/20 0.43
NTRK1 P04629 1/20 0.43
JAK2 O60674 3/20 0.42
CYP3A4 P08684 3/20 0.42
CYP2C8 P10632 3/20 0.42
CYP2C9 P11712 3/20 0.42
JAK1 P23458 3/20 0.42
TYK2 P29597 3/20 0.42
CYP2C19 P33261 3/20 0.42
JAK3 P52333 3/20 0.42
ADORA3 P0DMS8 2/20 0.42
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2203877 0.84 GSK3B (0.44) AURKAGSK3BAURKBSRCLMNA
SCHEMBL2205515 0.84 AURKA (0.72) AURKAGSK3BAURKBSRCAURKC
SCHEMBL2205693 0.84 AURKA (0.57) AURKAGSK3BAURKBSRCAURKC
SCHEMBL2205907 0.83 AURKA (0.67) AURKAGSK3BAURKBSRCAURKC
SCHEMBL2204682 0.83 AURKA (0.73) AURKAGSK3BAURKBSRCAURKC
SCHEMBL12430493 0.83 AURKA (0.71) AURKAGSK3BAURKBSRCAURKC
SCHEMBL2203023 0.83 AURKA (0.71) AURKAGSK3BAURKBSRCLMNA
SCHEMBL2203175 0.83 AURKA (0.56) AURKAGSK3BAURKBSRCAURKC
SCHEMBL2206175 0.82 AURKA (0.55) AURKAGSK3BAURKBSRCAURKC
SCHEMBL2203169 0.82 AURKA (0.48) AURKAGSK3BAURKBSRCAURKC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100408573-C Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMA (US) 2008-08-06 CN claimed
EP-1345926-B1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2006-05-17 EP claimed
CN-1486311-A Pyrazole compounds useful as protein kinase inhibitors ��̩��˹ҩ��ɷ����޹�˾ 2004-03-31 CN claimed
US-6653301-B2 For therapy of cancer, diabetes and Alzheimer's disease VERTEX PHARMACEUTICALS INCORPORATED 2003-11-25 US claimed
US-20030078275-A1 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2003-04-24 US claimed
US-7982037-B2 (5-Methyl-2H-pyrazol-3-yl)-(2-phenylsulfanyl-quinazolin-4-yl)-amine; Anticancer agents; antidiabetic agents; Alzheimer's disease; inhibitors of Aurora-2 and GSK-3 VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078275-A1 Pyrazole compounds useful as protein kinase inhibitors AURKC, AURKA, GSK3B AURKA 2/4885GSK3B 3/4885AURKB 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.